Notable Reporting: Affimed NV Can’t Be More Risky. Trades Sigfnicicantly Lower

Notable Reporting: Affimed NV Can't Be More Risky. Trades Sigfnicicantly Lower

The stock of Affimed NV (NASDAQ:AFMD) is a huge mover today! The stock decreased 5.40% or $0.15 during the last trading session, hitting $2.63. About 211,783 shares traded hands or 88.35% up from the average. Affimed NV (NASDAQ:AFMD) has declined 12.85% since February 29, 2016 and is downtrending. It has underperformed by 25.07% the S&P500.
The move comes after 5 months negative chart setup for the $89.07 million company. It was reported on Oct, 4 by Barchart.com. We have $2.26 PT which if reached, will make NASDAQ:AFMD worth $12.47 million less.

Analysts await Affimed NV (NASDAQ:AFMD) to report earnings on November, 8. They expect $-0.25 EPS, up 7.41% or $0.02 from last year’s $-0.27 per share. After $-0.27 actual EPS reported by Affimed NV for the previous quarter, Wall Street now forecasts -7.41% EPS growth.

Affimed NV (NASDAQ:AFMD) Ratings Coverage

Out of 7 analysts covering Affimed Therapeutics (NASDAQ:AFMD), 4 rate it a “Buy”, 0 “Sell”, while 3 “Hold”. This means 57% are positive. Affimed Therapeutics has been the topic of 13 analyst reports since August 6, 2015 according to StockzIntelligence Inc. The firm has “Outperform” rating by Wells Fargo given on Friday, December 4. Laidlaw initiated it with “Buy” rating and $15 target price in Thursday, December 10 report. Zacks upgraded the shares of AFMD in a report on Thursday, September 3 to “Hold” rating. Leerink Swann downgraded Affimed NV (NASDAQ:AFMD) on Thursday, May 19 to “Market Perform” rating. Leerink Swann downgraded the shares of AFMD in a report on Friday, August 12 to “Market Perform” rating. Zacks upgraded the stock to “Sell” rating in Monday, August 10 report. The company was initiated on Wednesday, September 9 by Jefferies. Oppenheimer maintained it with “Outperform” rating and $19 target price in Thursday, August 6 report. The rating was initiated by BMO Capital Markets on Tuesday, April 12 with “Outperform”. The firm has “Hold” rating by Jefferies given on Thursday, May 19.

According to Zacks Investment Research, “Affimed Therapeutics B.V. is a clinical-stage biopharmaceutical company. It is focused on discovering and developing cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology. The Company’s TandAbs has the ability to bring NK-cells or T-cells into proximity and trigger a signal cascade that leads to the destruction of cancer cells. Its product pipeline includes AFM13, AFM11 and AFM21. Affimed Therapeutics B.V. is headquartered in Heidelberg, Germany.”

More important recent Affimed NV (NASDAQ:AFMD) news were published by: Quotes.Wsj.com which released: “Affimed NV AFMD (US: Nasdaq)” on September 05, 2014, also Zacks.com published article titled: “Should You Get Rid of Affimed N.V. (AFMD) Now?”, Globenewswire.com published: “Affimed to Present at Upcoming Investor Conferences” on September 01, 2016. More interesting news about Affimed NV (NASDAQ:AFMD) was released by: Globenewswire.com and their article: “Affimed Enters into Collaboration with Merck to Evaluate AFM13 in Combination …” with publication date: January 25, 2016.

AFMD Company Profile

Affimed N.V., incorporated on May 1, 2014, is a clinical-stage biopharmaceutical firm focused on discovering and developing cancer immunotherapies. The Company’s product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body’s own immune system to fight tumor cells. The Company’s research and development pipeline consists of AFM13, AFM11, AFM21, AFM22, AFM24, TandAb and Trispecific Abs. The Firm generates its pipeline of product candidates from three platform technologies based on its tetravalent antibody architecture characterized by four binding domains, creating bispecific NK-cell and T-cell TandAbs (binding to two different targets) and Trispecific Abs (binding to three different targets). The Company’s bispecific antibodies, TandAbs, are designed to direct and establish a bridge between either Natural Killer (NK)-cells or T-cells and cancer cells. The Company’s TandAbs brings NK-cells or T-cells into proximity and triggers a signal cascade that leads to the destruction of cancer cells.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Leave a Comment